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To the editor:
Clinical outcomes of patients with acute myeloid leukemia: evaluation of genetic and molecular
findings in a real-life setting
Despite its undeniable importance, standard cytogenetic analysis is
still not a routine practice for most reference centers in developing
countries, and its accomplishment is practically limited to university
research centers. Particularly in Brazil, little is known about the
cytogenetic and molecular characterization of patients with acute
myeloid leukemia (AML), and results about clinical outcomes remain
scarce. In an effort to minimize the lack of results and contribute new
insights in our setting, we reported clinical features and outcomes of
241 nonselectedBrazilian patientswithAML (nonacute promyelocytic
leukemia) from 2 university hospitals, followed from November 2005
to April 2015.
Patients were classified according morphologic, immunopheno-
typic, and cytogenetic findings. Treatment protocols were similar
between centers. For patients up to 60 years of age, the treatment
protocol was adapted according to performance status and the presence
of comorbidities (in particular, cardiac disorders). Briefly, the conven-
tional chemotherapy consisted of daunorubicin (45-90 mg/m2 per
day for 3 days) and cytarabine (100-200mg/m2 per day for 7 days) or
thioguanine, cytosine arabinoside, and daunorubicin as induction,1
followed by 3 or 4 cycles of consolidation therapy with high doses
of cytarabine (.1 g/m2 per day). For patients who did not achieve
complete remission (CR) after 1 course of chemotherapy, a second
course was administered between days 28 and 35 after the end of the
first course.CRwas assessed by bonemarrow examination on day 28
after each course of chemotherapy. For those who needed it,
a postremission therapy based on autologous or allogeneic trans-
plantation was performed. Patients older than 60 years were treated
with low-dose cytarabine; a combination of etoposide, thioguanine,
and idarubicin; or best supportive care. The local research ethics board
of each participating center approved the study. Research was
conducted in accordance with the Declaration of Helsinki.
The baseline characteristics are summarized in supplemental
Table 1. One hundred thirty patients were enrolled in Recife
(northeast Brazil, 54%), and 111 patients were enrolled in Campinas
(southeast Brazil, 46%). Baseline features were similar between
centers. The median age was 47 years (range, 18-97 years) with 114
males (47%). Sixty-two patients (26%) were older than 60 years.
Pretreatment bone marrow samples were analyzed by G-banding
cytogenetics, of which 187 (78%) were successful. According to
Medical Research Council trials,2 patients were stratified as follows:
favorable (30/187, 16%), intermediate (119/187, 64%), and adverse
(38/187, 20%). Overall, 101 patients (42%) were cytogenetically
normal. To test whether the samples without cytogenetics results
were missing at random, the overall survival (OS) was evaluated for
patients with and without cytogenetics data. The 5-year OS rate did
not differ between patients with (18%) and without (23%) available
cytogenetics data (P 5 .372). Additionally, the entire cohort was
fully characterized for NPM1 and FLT3-ITD mutations. Details can
be found in the supplemental Data, available on the BloodWeb site.
Out of 241 enrolled patients, 39 patients (16%) who started
the induction treatment were lost to follow-up without assessment
for CR. Of 202 evaluable patients, 115 (57%) achieved complete
hematologic remission. CR rates according to the cytogenetic risk
stratificationwere 33%, 64%, and 77% for adverse, intermediate, and
favorable groups, respectively (P 5 .001). The logistic regression
analysis revealed that age (odds ratio [OR], 0.95; 95% confidence
interval [CI], 0.93-0.98; P5 .002) and cytogenetic risk stratification
(OR, 0.41; 95% CI, 0.19-0.89; P 5 .024) were independently
Figure 1. Patient survival. Probability of OS (A) and
DFS (B) in patients with AML according to cytogenetic
risk stratification.1 The percentages of each group are
presented on the graph. The “n” indicates the number
of patients included in each analysis.
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associated with CR. The median follow-up among survivors was
177 days (95% CI, 85-268 days). According to Medical Research
Council criteria, patients assigned to the adverse group exhibited
significantly shorter survival (85 days; 95% CI, 43-169 days) than
patients assigned to the intermediate (224 days; 95% CI, 72-375 days)
and favorable groups (241 days; 95% CI, 168-572 days) (P 5 .006;
Figure 1A). Age (hazard ratio [HR], 1.1; 95%CI, 1.01-1.2;P5 .029),
cytogenetic risk stratification (HR, 1.45; 95%CI, 1.02-2.06;P5 .036),
and white blood cell counts (HR, 1.03; 95% CI, 1-1.06; P5 .021)
were independently associated with poor OS. The median disease-
free survival (DFS) for adverse, intermediate, and favorable groups
was 392 days (95% CI, 37-1544 days), 650 days (95% CI, 208-
1091 days), and 668 days (95% CI, 57-1278 days), respectively. In
contrast to OS, cytogenetic risk stratification had no impact on DFS
(P 5 .578; Figure 1B).
In summary, we identified patients with favorable, intermediate,
and adverse outcomeswith frequencies very similar to those reported
by other groups.2,3 However, our patients’ clinical outcomes were
significantly inferior to those reported by developed countries. The
most significant difference was observed in the favorable group,
whose survival rate was significantly lower (39%) than rates reported
by studies conducted in the United States and Europe.2,4 Further-
more, the early mortality rate was especially higher in our cohort
(42%), which is probably a major cause of lower OS rate. Among
the main reasons for high early mortality in Brazil, we highlight the
lack of adequate hospital infrastructure, especially during induction
therapy.5,6 As a consequence, high incidence of bacterial and fungal
infections are frequently reported.7 It is important to note that our
results are representative of a real-life setting, which strongly differs
from the well-controlled clinical trials conducted in developing
countries.
Altogether, our results and others1,5,6,8 draw attention to an urgent
need for improved clinical support and treatment of patients with
AML in order to obtain results comparable to those reported in
developed countries. Such improvements may be achieved through
international collaborative efforts, which have already proved their
effectiveness in economically less privileged countries.A great example
is the International Consortium on Acute Promyelocytic Leukemia
study.9 This initiative considerably reduced the differences in
treatment outcome of patients with acute promyelocytic leukemia
between developed and developing countries through the dissem-
ination of knowledge and exchange of experience fromwell-established
cooperative groups in the United States and Europe. We hope that with
better hospital infrastructure and such initiatives, the clinical outcomes
of our patients will improve in the near future.
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To the editor:
GM-CSF stimulates granulopoiesis in a congenital neutropenia patient with loss-of-function
biallelic heterozygous CSF3R mutations
Severe congenital neutropenia (CN) is a heterogeneous disease char-
acterized by an absolute neutrophil count (ANC) below 500 cells
per microliter and recurrent, life-threatening bacterial infections.
Treatment with recombinant human granulocyte colony-stimulating
factor (rhG-CSF) was shown to increase ANCs in the majority of
patients and dramatically improves the quality of life.1 In a previous
study, we demonstrated major differences in responses to G-CSF and
granulocyte macrophage CSF (GM-CSF) in patients with CN.2 In the
majority of these patients, GM-CSF failed to induce neutrophil
granulocyte counts but did induce monocytosis and eosinophilia.2
Manyunderlying genetic defectshave been identified.Among themare
mutations in the ELANE, HAX1, and G6PC3 genes and many others.3
A recent study identified patients with biallelic loss-of-functionCSF3R
mutations whowere considered to have a novel subtype of CN.4 These
patients did not respond to G-CSF therapy, and no treatment options
were available for them. Heterozygous acquired mutations in the
CSF3R gene were also reported in CN patients.5
In this study, we identified a CN patient who did not respond
to G-CSF treatment. Three days after birth, the female patient was
diagnosed with CN with blood ANC below 250 cells per microliter.
White blood cell differential counts were as follows: 6% neutrophils,
7% monocytes, 4% eosinophils, and 83% lymphocytes. A bone
marrow (BM) evaluation at 3 weeks of age revealed granulopoietic
hypoplasia with reduction of all stages but no maturation arrest or in-
crease in blasts. Erythropoiesis, lymphopoiesis, andmegakaryopoiesis
were normal. No antineutrophil antibodies were detected. Mutational
screening revealed no mutations in ELANE, HAX1, or G6PC3. Cyto-
genetic evaluation revealed a normal karyotype.
Sequencing of the CSF3R gene showed 2 heterozygous mu-
tations in this patient that revealed a compound heterozygous
mode of inheritance of CSF3R mutations. In one allele intronic
mutation, c.998-2A.T leads to the skipping of exon 9 and intro-
duces an aberrant sequence downstream of exon 8 and a shift in
the reading frame. In the second allele, we detected a stop-codon
(p.W547*)mutation in the extracellular part of theG-CSF receptor
(G-CSFR) (Figure 1A). The p.W547*mutation was inherited from
the father and the c.998-2A.T mutation was inherited from the
mother.
No expression of G-CSFR was detected on the patient’s neutro-
phils or monocytes in contrast to blood cells from the healthy donors
(Figure 1B). Granulocyte macrophage CSFR (GM-CSFR) expres-
sion on CD331 cells from the patient’s BM was similar to that ob-
served for BM cells from healthy donors. In addition, we plated the
patient’s BM mononuclear cells in a semisolid medium supple-
mented with 10 ng/mL G-CSF, 10 ng/mL GM-CSF, or a cytokine
cocktail containingG-CSF, GM-CSF, interleukin-3, stem cell factor,
and erythropoietin, and cultured them for 14 days. No granulocyte
colony-forming unit (CFU-G), granulocyte macrophage CFU, or
macrophage CFU colonies were found in plates supplemented with
10 ng/mL rhG-CSF. In sharp contrast, all types of colonies grew on
plates containing either rhGM-CSF or the cytokine cocktail.
G-CSF treatment of this patient was initiated at the age of
3 weeks, but ANCs failed to increase with doses up to 110mg/kg per
day. At the age of 7 months, treatment with GM-CSF (6 mg/kg per
day) was initiated. In the first year of GM-CSF treatment, peripheral
blood ANCs ranged from 860 to 3744 cells per microliter, enabling
the GM-CSF dose to be reduced to 3 mg/kg per day twice a week
(Figure 1C). To evaluate whether GM-CSF was still required to main-
tain sufficient ANCs, GM-CSF administration was stopped with pro-
phylacticadministrationof oral antibiotics.Becauseof thedevelopment
of otitis media, GM-CSF treatment was restarted at a dose of 3 mg/kg
twice a week. This dose was sufficient to maintain the patient’s ANC
above 1000 cells per microliter and kept her free from infections. The
patient has remainedonGM-CSF treatment for the last 12yearswithout
any adverse events.
In summary, we provide the first demonstration of the success-
ful treatment of a CN patient harboring biallelic loss-of-function
CSF3Rmutations who did not respond to G-CSF by administering
GM-CSF. These findings suggest that all CN patients who do
not respond to G-CSF should be screened for germ-line CSF3R
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